Longevity Therapies

A longevity therapy is an intervention aimed at ageing itself rather than at any one of the diseases ageing produces. The premise is that cardiovascular disease, cancer, dementia and frailty share upstream drivers, and that hitting a driver would move all of them at once. That premise is the field's whole claim, and it is not absurd: it is the same logic that made statins matter more than treating heart attacks one at a time.

This brief is about the drugs and protocols, not the mechanisms. Resetting cells is Cellular Rejuvenation; the whole-organism claim is Biological Immortality. Here the question is narrower and more testable: which compounds have been given to which animals, at what age, with what measured outcome, and what happened when they reached people.

The subject has one asset no other area of biomedicine possesses — a public, blinded, three-site replication facility that runs mouse lifespan studies to a fixed standard — and one deficit that overwhelms it. Ageing is not a recognised indication. There is no approvable endpoint, therefore no trial design a regulator will accept, therefore no reimbursement, therefore no capital for the cheap generic drugs that carry the best evidence. The result is a field whose strongest candidates are off-patent and untested in humans, and whose best-funded work is on interventions that have never been through the replication facility at all.

The framing under test throughout is the sentence a reader will have absorbed from coverage: drugs that extend lifespan in mice are approaching human use. The first half is true for a small number of compounds, with qualifications the coverage drops — the effect sizes are single-digit to low-double-digit percentages, several are male-only or female-only, and at least four widely repeated figures describe a quantity other than lifespan. The second half is not a claim about biology at all. It is a claim about institutions, and the institutions have said no for ten years running.

Established Rapamycin is the only compound with a mouse lifespan result the field genuinely trusts, and the result is smaller and more sex-dependent than its reputation. Harrison, Strong, Sharp and colleagues fed encapsulated rapamycin to genetically heterogeneous mice beginning at 600 days of age — animals already old — and reported increases in both median and maximal lifespan in both sexes: +14% in females and +9% in males, with a secondary cohort started at 270 days. Frontier What made the paper matter was not the effect size but the timing: it worked in animals that had already lived most of their lives, which is the only version of the result with any bearing on treating human adults, none of whom will be enrolled from birth.

Established That result is trustworthy because of an apparatus, and the apparatus deserves to be named before any of the chemistry. The NIA Interventions Testing Program has run since 2002 across three sites — the Jackson Laboratory, the University of Michigan, UT Health San Antonio — with a data coordinating centre added in 2019. Established Every agent is fed to specific-pathogen-free male and female UM-HET3 genetically heterogeneous mice at all three sites simultaneously under a standardised protocol, with enough animals to give 80% power to detect a 10% increase in lifespan for either sex when sites are pooled, and up to six agents a year are accepted by open nomination. Frontier No other area of biomedicine has anything comparable, which is why most fields cannot say whether their headline results replicate and this one can.

Established What the programme has actually found is a pattern almost nobody repeats: the effects are frequently sex-specific. Rapamycin extends lifespan in both sexes with a dose-response — higher dose, longer lifespan. Established Acarbose shows a substantially greater effect in males. Established Canagliflozin, in the programme's own words, extends lifespan in male but not female mice, and the programme's first positive report, on nordihydroguaiaretic acid and aspirin in 2008, was male-only in its title. Frontier A brief that reports “drug X extends lifespan” without the sex term is discarding the most reproducible structure in the entire dataset. Speculative Nobody has a settled account of why so many geroprotectors are male-biased; the candidates run from pharmacokinetics to sex differences in mTOR signalling to differing baseline causes of death, and none is established.

Established Rapamycin in humans is now one randomised year, and its primary endpoint failed. The PEARL trial randomised 125 healthy adults, of whom 114 completed, to weekly oral placebo, 5 mg or 10 mg compounded rapamycin for 48 weeks, decentralised and double-blind. Established Safety was reassuring: adverse events similar across arms, more gastrointestinal complaints on drug, blood biomarkers within normal ranges. Established The primary endpoint — visceral adiposity — showed no significant change. Frontier The significant secondary findings were sex-split in the opposite direction to the mouse data: women on 10 mg gained lean tissue mass (p=0.013) and reported less pain (p<0.001), while all participants on 5 mg reported improved emotional well-being (p=0.023) and general health perception (p=0.004). Established The authors' caveats are candid: self-reported adherence, a health-conscious low-BMI cohort, small n, and compounded rapamycin having roughly one third the bioavailability of commercial formulations. Established All seven listed authors are employees and shareholders of AgelessRx, the telehealth company that sells the drug. Frontier This is nonetheless the best human rapamycin-for-ageing evidence in existence, which is the most informative fact in the paragraph.

Established Metformin's flagship trial has been fully designed, publicly endorsed and never started. TAME — Targeting Aging with Metformin — is a six-year study of more than 3,000 people aged 65–79 across 14 research institutions, coordinated from Wake Forest, testing whether metformin delays a composite of incident cardiovascular disease, cancer and dementia. Established The FDA endorsed the trial concept in 2015. The cost is $30–50 million; NIH contributed roughly $9 million, for biomarker work only; the gap is $21–41 million; and the American Federation for Aging Research is still, on its own page, soliciting donors to help launch it. Established Nir Barzilai, its principal advocate, said in 2022: “I'm on the record saying I'm pretty sure it will start this year, for the last seven years. I have no credibility anymore.” On why the money does not come: “Those big billionaires, they want moonshots... TAME is not a moonshot.” And on what the trial is actually for: “There's nothing in that clinical trial that hasn't already been shown before with metformin. We are just trying to package it all up and call it aging so the FDA will approve this for aging.” Frontier That last quote is the honest description of TAME: it is a regulatory manoeuvre wearing a trial's clothes, and its designer says so.

Established Senolytics have the field's cleanest proof of concept and the field's most misreported result, in the same 2011 paper. Baker, Wijshake, Tchkonia and colleagues built the INK-ATTAC transgene, which kills p16-positive cells on command, and showed in progeroid BubR1 mice that lifelong clearance delayed pathology in adipose tissue, skeletal muscle and eye. Established The same paper states that “the overall survival of AP20187-treated BubR1H/H;INK-ATTAC mice was not substantially extended” — the animals died of cardiac failure through a p16-independent route. The abstract's claim is healthspan, in the title. Established The lifespan result arrived five years later in a different paper: Baker, Childs, Durik et al. dosed INK-ATTAC mice twice weekly from one year of age on two genetic backgrounds and extended median lifespan in both backgrounds and both sexes, with delayed tumorigenesis. Frontier Both papers are genetic models. The pharmacological result came in 2018: intermittent oral dasatinib plus quercetin in 24- to 27-month-old mice “increased post-treatment survival by 36% while reducing mortality hazard to 65%”, alongside a companion finding that transplanting small numbers of senescent cells into young mice caused persistent physical dysfunction within two weeks. Established The 36% is post-treatment survival in animals already near the end of a mouse lifespan. It is not a 36% lifespan extension, and the difference is the subject of section 14.

Established In humans the senolytic record is thinner than the enthusiasm and points in more than one direction. The first-in-human study gave dasatinib plus quercetin to 14 older adults with idiopathic pulmonary fibrosis over three weeks — nine doses in total — and reported a mean 21.5 metre improvement in six-minute walk distance. Established Grip strength and pulmonary function did not change, the study was open-label, uncontrolled, n=14, and its investigators urged caution about whether the finding was real at all. Frontier The randomised follow-up in the same indication states its endpoints as feasibility and tolerability; the most advanced senolytic programme, UBX0101 in knee osteoarthritis, reached randomised double-blind phase 2 and was discontinued after the read-out. Frontier And a cohort of 19 people on dasatinib and quercetin for six months showed increased epigenetic age acceleration on earlier-generation clocks and decreased telomere length — small, uncontrolled, scored on contested clocks, and cited far less than the mouse work.

Established Caloric restriction is the oldest intervention in the field and the primate literature contradicts itself for a reason worth knowing. Two long-running rhesus studies reached opposite conclusions. The Wisconsin cohort (n=76) found a significant survival benefit, with control animals carrying nearly twice the mortality (hazard ratio 1.865); the NIA cohort (n=121) found no significant survival difference for juvenile- and adolescent-onset animals. Established The 2017 joint analysis attributes the divergence to three things: NIA control monkeys were not free-fed, so the comparison was restriction against moderate restriction; NIA started animals much younger while Wisconsin began in adulthood; and the diets differed fundamentally, with Wisconsin's semi-purified chow at 45% sucrose as a fraction of carbohydrate against NIA's 7%. Frontier The honest summary is that caloric restriction reliably improves health markers in primates and that its survival effect depends on what the comparator eats. Frontier The human counterpart, the CALERIE randomised trial of sustained moderate restriction in non-obese adults, reported improvements in cardiometabolic risk markers with achieved restriction well below its target, and a later analysis reported a small slowing of a pace-of-ageing measure. This brief's sourcing pass did not obtain the CALERIE primary papers; no figure from them is printed here, and the claim is carried at frontier strength only.

Frontier Plasma dilution is the field's most elegant experiment and its thinnest human dataset. Mehdipour, Conboy and colleagues replaced roughly half of an old mouse's plasma with saline plus 5% albumin — a fluid containing nothing young whatsoever — and reported enhanced muscle repair, reduced hepatic adiposity and fibrosis, and increased hippocampal neurogenesis at levels that met or exceeded heterochronic blood sharing. Frontier A companion study in 22- to 24-month-old mice restored whisker discrimination to young levels (p<0.00001 against old untreated) and returned activated microglia to young values — on behavioural groups of n=4. Frontier The human data are eight therapeutic plasma exchange patients aged 60–77, uncontrolled and unblinded, reporting biological age “reduced by decades” on a bespoke ten-protein noise biomarker developed by the same group. Speculative The mechanistic claim — that the active principle is removal of age-elevated factors rather than addition of youthful ones — is the most interesting idea in this brief, and it rests on one well-designed paper with no independent replication.

Frontier The remaining categories are where the money is and the evidence is not. NAD precursors (nicotinamide riboside, nicotinamide mononucleotide) reliably raise circulating NAD+ in human trials; the trials that measured function have not produced a consistent clinical benefit in healthy older adults, and the gap between “the biomarker moved” and “the person is better” is the whole problem. Established A heavily promoted 2023 claim that taurine deficiency drives ageing, published with a supportive commentary in Science, now has a 2025 Aging Cell paper against it whose title is the finding: “Experimental evidence against taurine deficiency as a driver of aging in humans.” Frontier And exercise is the unflattering benchmark every candidate is measured against and none has matched. Cardiorespiratory fitness carries among the largest and most consistent associations with all-cause mortality in the epidemiological literature, at effect sizes no geroprotector has approached in a human trial, at a cost of zero — and its causal fraction is contested for exactly the reason every supplement study is confounded and does not say so: fit people are partly people who are not already ill. The reading list carries no fetched primary source for the NAD-precursor trials or the exercise-mortality literature; both are stated at frontier strength and no number is printed from either. Handwave Meanwhile the retail market in compounds sold for longevity is, on every published estimate, larger by orders of magnitude than the entire public budget testing whether any of them work. No figure is printed here because none could be sourced; the ordering is not disputed by anyone in the field.

Frontier The single sharpest open question is whether anything in this brief is measured on a valid endpoint. A human longevity trial cannot use lifespan, so it uses an epigenetic clock or a disease composite. Frontier The clocks were built to predict chronological age and were then repurposed as outcome measures, which is a different job — and a human senolytic cohort moved them the wrong way. Speculative If clock deltas do not predict subsequent morbidity and mortality within individuals, every positive and every negative human result in this field is uninterpretable, the failures as much as the successes. This is not a hedge; it is a specific, testable, currently unanswered proposition.

Frontier Does the sex asymmetry reconcile? Rapamycin favoured females on lifespan in the 2009 study, favoured males under the transient high-dose injection protocol, and produced its significant human findings in women. Frontier Acarbose and canagliflozin favour males. Speculative No account currently predicts which way a new compound will split, which means the field cannot design a dose without running both sexes — and most commercial human trials are not powered to.

Speculative Is dilution the mechanism, or are young factors real after all? The saline-albumin exchange is a genuinely discriminating experiment and it came out on the dilution side. Frontier What is missing is a dose-response: does the effect scale with dilution factor, and does it reproduce with an inert replacement fluid in another laboratory? Speculative If yes, therapeutic plasma exchange — an approved procedure with decades of safety data — becomes the most immediately deployable intervention in the entire field, and the young-plasma industry was selling the wrong half of its own mechanism.

Speculative Are senescent cells load-bearing? Senescence is a tumour-suppressive mechanism and a wound-healing mechanism before it is a pathology. Frontier The genetic models kill a defined p16-positive population; small molecules like dasatinib and quercetin do not, and their selectivity is inferred rather than demonstrated. Frontier The evidence against the worry is that the 2016 clearance study reported reduced tumorigenesis; the worry's strongest form is that nobody has run wound-healing and lifetime-tumour endpoints in animals on long-term small-molecule senolytics.

Speculative Is the senolytic effect just an anti-inflammatory effect? If clearing senescent cells works by removing the senescence-associated secretory phenotype, a senomorphic that suppresses the secretome without killing anything should do the same job with less risk. Frontier The discriminating experiment — senolytic against senomorphic, matched on inflammatory-marker reduction, compared on functional endpoints — does not appear to have been run. Handwave A deflationary version goes further: much of geroscience may be measuring chronic inflammation under different names, in which case the hallmarks framework is a taxonomy of symptoms.

Speculative Can a single-target drug work on a multi-hallmark process at all? The canonical framework now lists twelve hallmarks. Speculative If ageing is twelve partly independent failure modes, then a drug hitting one buys you the fraction of mortality that mode contributes and no more, and the ceiling on single-agent effect sizes is structural rather than pharmacological — which would explain why nothing in the ITP has ever produced a large number. Speculative The counter-argument is that the hallmarks are not independent: mTOR sits upstream of several, which is why rapamycin is the compound that works. Frontier This is a real disagreement among serious people and it is unresolved. Speculative It has a direct experimental consequence — if the multi-hallmark view is right, combination protocols are not an optimisation, they are the only route — and nobody has tested combinations at ITP standard.

Speculative Is the ITP's own null result being read correctly? The programme has tested dozens of nominated compounds and most produced nothing. Frontier The enthusiast reading is that the survivors are therefore real. Speculative The deflationary reading is that a facility powered for a 10% effect will find only 10% effects, and that the distribution of true effect sizes may be a mass of 2–4% signals that the design cannot see and would not be worth taking a drug for anyway. Handwave Nobody has published the meta-analysis of ITP nulls that would distinguish those readings, and it would be a genuinely valuable paper.

Speculative And the question underneath all of them: is any of this better than exercise? No candidate in this brief has been compared head-to-head against a structured exercise intervention in a human trial with matched endpoints. Frontier Given that cardiorespiratory fitness carries the largest and most consistent mortality associations available in human data, the absence of that comparison is conspicuous. Handwave A trial that randomised older adults to a geroprotector, to supervised exercise, and to both, on a shared functional endpoint, would be the most informative study the field could run and would also be the one most likely to embarrass it.

Established The binding bottleneck is not a molecule, a delivery system or a mechanism. It is that ageing is not an indication. Because there is no recognised disease, there is no approvable endpoint; without an endpoint there is no trial a regulator will accept; without an acceptable trial there is no label; without a label there is no reimbursement; and without reimbursement no commercial actor can recover the cost of testing an off-patent drug. Established Every downstream problem in this brief is a consequence of that chain, and TAME's composite-endpoint design exists specifically to break it at the first link.

Established The second bottleneck is the generic-drug trap, and it is a market-design failure with a precise price. Metformin and rapamycin are both off-patent and cost pennies. Established No one can recover $30–50 million by selling them, so no one funds the trial that would prove them. Frontier The vacuum is filled by companies that sell the drug and also run the study — which is how the only randomised year-long rapamycin trial in healthy adults came to be staffed entirely by shareholders of the vendor. Frontier That is not an accusation of misconduct; it is a structural description of what happens when the public sector declines to fund the obvious experiment.

Frontier The third is endpoint validity — treated in section 3, and cheap to resolve relative to everything else here.

Established The fourth is throughput on the one facility that works. The Interventions Testing Program accepts up to six agents per year. Established Senolytics, plasma dilution and partial reprogramming have never been through it. Frontier A full combinatorial design across four compounds is fifteen arms — more than two years of national capacity for one question. Frontier That is a funding decision presented as a scientific limitation: the constraint is the size of an appropriation, not the difficulty of the biology.

Frontier The fifth is that mouse lifespan studies take three years and human ones take decades, which sets a hard clock on iteration. Speculative No amount of capital compresses it, and every proposal to do so — surrogate endpoints, in vitro clocks, AI-predicted geroprotectors — is a proposal to substitute a proxy whose validity is the unresolved question in section 3. Frontier The clock is also why the field's evidence base is structurally biased toward whatever was fashionable three years ago rather than what is fashionable now.

Speculative The sixth is a bottleneck of attention rather than of resource. The sex-specificity result has been in the literature since 2008 and is still absent from most secondary accounts; the Baker 2011 correction is a single sentence in a paper anyone can read; the conditional-versus-total distinction requires no equipment at all. Frontier A field that cannot propagate corrections through its own review literature will not propagate them through a marketing department, and the consumer market is where most people meet this subject.

Established This brief depends on two others for its mechanistic content and supplies both with its regulatory reality. Biological Immortality asks whether the hazard function can be flattened at all and supplies the comparative-biology targets — the naked mole-rat, the hydra, the bowhead — from which single-gene interventions are being drawn. Frontier Cellular Rejuvenation supplies the epigenetic clocks that every human trial in this brief uses as an endpoint, and therefore owns the validity question this brief cannot answer for itself.

Established The dependency runs the other way too, and harder. Reprogramming, senolytics and plasma exchange all face the same absent indication. Frontier A validated surrogate endpoint accepted by a regulator would unblock all three simultaneously; nothing else in the cluster has that property. Established It is also the reason a $3 billion private reprogramming venture and a $21–41 million public trial shortfall coexist: capital flows to the moonshot framing because the incremental framing has no route to a label either.

Frontier Scientifically, the field waits on three inputs it does not produce. Biomarker science, which lives partly in Cellular Rejuvenation; comparative demography, which lives in Biological Immortality; and clinical-trial methodology for composite endpoints in ageing populations, which lives nowhere in particular and is nobody's career. Speculative The third is the most neglected and possibly the cheapest to fix: designing a composite endpoint for a healthy older population, and getting a statistician and a regulator to agree on it in advance, is methodological work that no funding stream currently pays for and that would unblock more than any new molecule.

Frontier There is also a dependency the field does not name, which is a supply of comparators. Every intervention here is implicitly measured against doing nothing, and none is measured against exercise, dietary change, or the existing preventive pharmacopoeia of statins and antihypertensives. Speculative Until a trial includes an active lifestyle arm, the field cannot say whether a geroprotector adds anything on top of what is already available for free, which is the only question a health system will ask when the label finally arrives.

Frontier The workback plan has nine links and the first one is cheap, decisive and unfunded. (1) Validate the endpoint. Take existing biobanks with repeat sampling and test prospectively whether epigenetic-clock deltas predict subsequent morbidity and mortality within individuals rather than across them. Frontier The data already exist; the cost is analytic. Speculative It is also the study the field's commercial actors have least incentive to run, because a null result invalidates the endpoint they sell against.

Established (2) Get a regulator to accept an endpoint — TAME's incident-disease composite, or a surrogate validated by link 1. Established (3) Fund one adequately powered generic-drug trial. TAME is designed, endorsed and costed; the missing input is $21–41 million. Frontier (4) Make sex-specific dosing standard, by reporting every compound with sex terms and dose-response as a condition of publication. This link is scientifically almost complete and communicatively a failure.

Frontier (5) Put the untested interventions through the replication facility. Senolytics, plasma dilution and partial reprogramming have never faced three sites, two sexes, heterogeneous mice and 80% power for a 10% effect. Speculative There is no strong reason to expect them all to survive it, and that is the point. Frontier (6) Resolve dilution against young factors with a dose-response using inert replacement fluid, in a laboratory that did not produce the original result. Frontier (7) Separate senolytic from senomorphic effects head to head, matched on inflammatory-marker reduction. Speculative (8) Run one real combination study at ITP standard, with lifetime tumour incidence as a co-primary endpoint rather than an afterthought.

Speculative (9) What a real human longevity trial would have to look like. Tens of thousands of participants aged 60–80; a pre-registered composite of first incident major age-related disease; both sexes powered separately; a placebo arm maintained for six or more years; adjudicated events; and an intervention cheap enough that the answer is deployable if positive. Frontier TAME is that trial at the smallest defensible size, which is why its non-existence is the most informative fact in this brief. Handwave A trial powered on all-cause mortality in a healthy population would need a cohort and a duration that no funder in the world has ever committed to a non-communicable-disease question.

Frontier Very little here is an engineering problem, and pretending otherwise is one of the field's habits. Rapamycin, metformin, dasatinib, quercetin, fisetin and acarbose are all manufactured at scale already. Established The one genuine formulation issue is documented: compounded rapamycin used in the human trial has roughly one third the bioavailability of the commercial product, which means dose comparisons across studies are not comparable without a pharmacokinetic bridge.

Frontier Where engineering does bind is delivery and selectivity. Small-molecule senolytics kill by exploiting anti-apoptotic dependencies that senescent cells share with other stressed cells; a tissue-targeted senolytic — antibody-drug conjugate, chimeric antigen receptor T cell, or a prodrug activated by senescence-associated beta-galactosidase — would convert an inferred selectivity into a designed one. Speculative Each of those exists as a published concept; none has a lifespan result at ITP standard.

Frontier Plasma exchange is the one intervention here with an existing device base. Apheresis machines, disposables, vascular access and trained operators all exist because therapeutic plasma exchange is an approved procedure for other indications. Speculative Repositioning it needs no new hardware, which makes it the cheapest thing in the brief to test at scale and among the least tested.

Speculative The dosing regimen is itself an engineering variable that is under-explored. The transient-treatment result — 90 days of rapamycin in middle age, then stop — suggests that intermittent exposure may capture much of the benefit at a fraction of the immunosuppressive cost. Frontier Nobody has mapped the schedule space systematically in any species, and the schedule space is larger than the compound space: dose, interval, duration, age at start and age at stop are five axes, and the replication facility varies at most two of them per agent.

Speculative The one genuinely unsolved manufacturing question is the senolytic prodrug. A molecule that is inert until cleaved by an enzyme enriched in senescent cells would convert the whole class from a systemic cytotoxic exposure into a targeted one, and would make chronic dosing thinkable. Frontier Candidate activation chemistries exist in the literature; none has an in vivo lifespan result, and the enzyme most often proposed as the trigger is not specific to senescent cells either.

Established The nearest neighbour is metabolic pharmacology, and it arrived by accident. Acarbose and canagliflozin are both diabetes drugs; both produced male-biased lifespan extension in the replication programme. Frontier GLP-1 receptor agonists are now read for age-related signals on the strength of cardiovascular and renal results obtained for other reasons. Speculative The pattern is worth naming: the geroprotectors with the best evidence were all developed for something else, and none was designed against a hallmark.

Frontier Oncology is adjacent in both directions. Dasatinib is a cancer drug; rapamycin analogues are cancer drugs; and the adverse finding in the transient-rapamycin study was a shift in cancer type in high-dose females toward aggressive haematopoietic malignancies. Frontier Any intervention that changes cellular turnover changes cancer risk, in a direction that has to be measured rather than assumed.

Frontier Transplant immunology supplies rapamycin's entire human safety database — at doses far above those used in geroscience, in patients immunosuppressed on purpose. Speculative Extrapolating that record downward to weekly low-dose use in healthy people is a real inferential leap, usually made silently. Speculative Further out sit the preservation technologies — Brain Preservation and Cryonics — the wager you make if you conclude nothing here will arrive in time.

Frontier Apheresis medicine is the adjacency with the shortest path to a patient. Therapeutic plasma exchange is an approved procedure with a mature device base, established reimbursement in its existing indications, and decades of safety data in populations far frailer than the ones a longevity trial would enrol. Speculative Almost nothing else in this brief has any of that, and the fact that the field's most deployable modality is also its least funded is a fair summary of how capital is allocated here.

Speculative Finally, exercise physiology and nutrition science are adjacent in the awkward sense. They own the only interventions with large, consistent, replicated associations with human mortality; they are not thought of as longevity science; and no compound in this brief has been tested against them. Frontier The intellectual traffic runs one way — geroscience borrows caloric restriction and ignores the exercise literature — and the borrowing is selective.

Established The institutional story of this field is one facility that works, one trial that does not exist, and a capital allocation that explains both. The Interventions Testing Program is a public good of a kind biomedicine rarely builds: blinded, multi-site, adversarially designed against its own investigators' hopes, running since 2002. Established It costs a small fraction of what a single private longevity company raises and it is the only reason anyone can say which mouse results are real.

Established Against that, the arithmetic on TAME. Designed, FDA-endorsed since 2015, coordinating centre named, sites named, cost $30–50 million, raised ~$9 million for biomarker work, gap $21–41 million, launched never. Established In January 2022 a single private cellular-reprogramming company launched with $3 billion. Established The ratio between that sum and TAME's shortfall is between roughly 70 and 140 to one. Frontier No scientific fact separates them. What separates them is that one is a moonshot and the other is a six-year trial of a drug that costs pennies, and the field's own most senior advocate says exactly that in public.

Frontier The consequence is that the commercial layer now generates most of the human data. The randomised rapamycin trial was run and staffed by a company selling compounded rapamycin. Frontier The human senolytic clock cohort came through a commercial testing platform. Frontier The human plasma-exchange endpoint is a biomarker proprietary to the group reporting it. Established None of this invalidates the work and all of it should be marked every time it is cited, which is what this brief has done.

Speculative The institutional fix is a market-design instrument, not a discovery. An advance market commitment, a prize, or a standing public fund for adequately powered trials of off-patent compounds against age-related composites would convert a decade of inaction into a queue of trials. Handwave Nobody has built one, and the reason is that the constituency for a generic drug is everyone, which is to say nobody. Speculative The cheapest version is not an instrument at all: a single line item in a national research budget, at the scale of a mid-sized cancer trial, standing ready for off-patent geroprotectors. Frontier The fact that ten years of advocacy by the field's most senior figures has not produced one is the strongest available evidence that the obstacle is institutional design rather than scientific merit.

Frontier The dominant present harm in this field is not inequitable access to a working therapy. It is the sale of unproven compounds to healthy people. Because there is no approved pathway, an unregulated one has filled the space: supplements, compounded prescriptions, clinics, and biological-age tests sold as outcome measures. Established The young-plasma industry is the documented instance — a market built on the belief that something in young blood is therapeutic, in the face of the field's own best experiment showing the benefit came from a saline-albumin exchange containing nothing young at all. This brief's sourcing pass did not retrieve the 2019 FDA safety communication on young-donor plasma; it is named here and no quotation from it is printed.

Frontier Treating healthy people changes the risk calculus completely. A 5% chance of serious harm is acceptable in metastatic disease and unacceptable in a 55-year-old who feels fine. Established The transient-rapamycin study's finding of aggressive haematopoietic cancers in high-dose injected females is exactly the kind of signal that a healthy-population intervention cannot carry, and it is rarely mentioned in consumer-facing accounts of the same paper.

Speculative Equity cuts both ways here, and the usual framing has it backwards. The compounds with the best evidence are off-patent and cost pennies; if any of them worked, they would be among the most equitably distributable interventions ever developed. Frontier The inequity is upstream, in who can afford to self-experiment while the evidence is absent, and downstream, in who would be enrolled in a six-year trial that nobody is funding.

Speculative There is a consent problem specific to surrogate endpoints. A participant told that their biological age fell has been told something whose meaning is unresolved. Handwave Selling that number as a health outcome, before the prospective validation in section 6 has been run, is closer to fortune-telling than to medicine — and it is a large and growing consumer market.

Frontier The realistic prize is compressed morbidity, and it is enormous even at unglamorous effect sizes. A therapy that delayed the onset of the major age-related diseases by two or three years across a population would move more disability-adjusted life years than most of twentieth-century medicine, without extending maximum lifespan at all. Frontier That is what the geroscience hypothesis actually promises, and it is consistently undersold by its advocates in favour of larger claims that the evidence does not carry.

Speculative The fiscal case for testing is unusually clean. Age-related chronic disease dominates health spending in every developed economy. Speculative An intervention costing pennies that delayed the composite by even a small margin would repay a $50 million trial many times over within a single budget cycle, which makes the decade of non-funding a genuinely strange institutional fact rather than a rational allocation.

Speculative Larger extensions raise harder questions that the evidence does not yet license anyone to ask urgently. Pensions, tenure of political and economic power, generational turnover in ideas, and the distribution of a positional good. Handwave A world where the wealthy reliably outlive the poor by decades rather than years is a different political order, and the first mover would be a jurisdiction, not a person.

Frontier The near-term civilizational consequence is more mundane and already happening: a large consumer market has formed around interventions with no demonstrated effect on human ageing. Speculative If the field's endpoints turn out to be invalid, the correction will be a credibility event on the scale of the antioxidant era, and it will make the next round of real evidence harder to fund. Frontier That risk is itself an argument for running the cheap endpoint-validation study first rather than last: the field is currently accumulating a liability it has chosen not to price.

These horizons track regulatory and evidentiary milestones rather than the discovery of new compounds, because the compounds already exist. What does not exist is a way to prove anything about them in people. Every date below is therefore a prediction about institutions, and the honest caveat is that institutional timelines are the ones this field has consistently got wrong: TAME was going to start every year for at least seven years.

• 5 yr: Frontier Prospective within-individual validation of epigenetic-clock endpoints is runnable on existing biobank data today, needs no new cohort, and could report inside this window if anyone funded the analysis. Frontier Whether TAME launches is a funding decision that could resolve in either direction at any moment and has resolved neither way for ten years. Speculative An independent replication of the saline-albumin plasma-dilution result is cheap enough to appear on this horizon.
• 10 yr: Frontier Plausibly the first regulatory acceptance of a composite age-related-disease endpoint, most likely through TAME or a successor built on the same argument. Speculative Senolytics reaching approval, if at all, in a defined tissue indication — fibrosis, osteoarthritis, diabetic kidney disease — and not for ageing. Speculative Plasma exchange either repositioned on the strength of a dilution dose-response or quietly abandoned once one is attempted. Speculative The first ITP-standard combination arm, if the facility's throughput is expanded.
• 25 yr: Speculative The first intervention shown to slow a measured ageing process in humans against a regulator-accepted endpoint — conditional entirely on the 10-year link landing, and worthless without it. Speculative Combination protocols tested at replication-facility standard rather than assembled and sold as stacks. Handwave If the multi-hallmark objection is right, this is also the horizon on which the field discovers that its single-agent ceiling is structural.
• 50 yr: Speculative Compressed morbidity as routine preventive medicine: sex-specific dosing standard, generic geroprotectors reimbursed, and prevention of the age-related composite treated as one clinical problem. Speculative Effect sizes most plausibly a few added disease-free years rather than decades — which would still be among the largest public-health gains ever recorded.
• 100 / 250+ yr: Handwave Multi-hallmark combination therapy producing large human lifespan extension. Nothing in the present evidence base licenses a number: the ceiling on single-agent effects is unknown, the ceiling on combinations has never been measured in any mammal, and the demographic question of whether a fixed human maximum exists at all is unsettled in Biological Immortality. Handwave Anyone quoting a date here is quoting a preference.

• Depends on Two briefs, in different currencies. Biological Immortality supplies the comparative-demography and hazard-function work — whether an age-specific mortality curve can be flattened at all, what the naked mole-rat and the hydra actually show, and the standing null result that no mammal has been demonstrated non-senescent outside protected captivity. That brief sets the ceiling this one is pushing against, and it also supplies the single-gene targets that comparative biology is now beginning to move between species. Cellular Rejuvenation supplies something more immediately load-bearing: the epigenetic clocks. Every human trial named in this brief is scored, directly or indirectly, on a biomarker that brief owns, and the unresolved question of whether a moving clock means anything is therefore an input to this brief that this brief cannot resolve for itself. Where those two briefs disagree with each other — on whether ageing is damage or information loss — this brief has to hold both readings open, because the drugs on offer are damage-directed and the endpoints are information-directed.
• Enables One output dominates: a validated, regulator-accepted endpoint for ageing. It is the single result that would unblock this brief, the reprogramming brief and the wider geroscience programme simultaneously, because all three fail at the same place for the same reason. Downstream of it: compressed morbidity as a reimbursable clinical goal rather than an aspiration; sex-specific geroprotector dosing as standard practice rather than a finding nobody repeats; a route by which cheap off-patent compounds can be proven rather than merely sold; and a trial architecture — composite incident-disease endpoints, adjudicated events, both sexes powered separately, six-year placebo maintenance — that ageing research does not currently possess and would have to build once. Further out, an approved geroprotector is the precondition for treating age-related disease prevention as a single clinical speciality instead of as the residue left over by cardiology, oncology and neurology.
• Adjacent Metabolic pharmacology is the closest neighbour and the least expected one: acarbose and canagliflozin are diabetes drugs that produced male-biased lifespan extension, and GLP-1 receptor agonists are now being read for geroprotective signals obtained for entirely other reasons. Oncology is adjacent in both directions — dasatinib and the rapalogues are cancer drugs, and lifetime tumour incidence is the endpoint every intervention here has to survive. Transplant immunology supplies rapamycin's whole human safety record, at doses far above geroscience use and in patients immunosuppressed on purpose. Apheresis medicine supplies the device base, the disposables and the trained operators that make plasma exchange the cheapest thing in the brief to test at scale. And the preservation technologies — Brain Preservation and Cryonics — are adjacent as the wager you make if you conclude nothing here will arrive in time.

Established This field has one signature error and it appears in four separate papers' receptions. A real result about a conditional quantity — survival after treatment, remaining life at extreme old age — is restated as a result about the unconditional quantity, total lifespan. It is always in the same direction and the magnitude of the exaggeration runs from a factor of two to a factor of fifteen. Naming the denominator is the whole correction.

Established “Clearing senescent cells extends lifespan — proved in 2011.” Baker et al. 2011 states, in the paper, that “the overall survival of AP20187-treated BubR1H/H;INK-ATTAC mice was not substantially extended”; the animals died of cardiac failure through a p16-independent mechanism, and the paper's claim is healthspan. Anyone citing Baker 2011 for lifespan extension has cited a source that contradicts them. The lifespan result is Baker et al. 2016, a different paper, in normally-ageing mice.

Established “Senolytics extended the lifespan of old mice by 36%.” Xu et al. 2018 reports that dasatinib plus quercetin “increased post-treatment survival by 36% while reducing mortality hazard to 65%” in mice that were already 24 to 27 months old. Post-treatment survival in animals near the end of their lives is a conditional quantity. It is not a 36% lifespan extension and the paper does not say it is.

Established “Ninety days of rapamycin in middle age extended lifespan 60%.” Bitto et al. 2016 reports +60% median post-treatment life expectancy and +14% overall lifespan in the injected cohort — and only in males (females showed no significant benefit). The dietary cohort gave +42% post-treatment and +13% overall, in both sexes. Established The paper also reports that high-dose injected females showed “a striking shift in cancer prevalence toward aggressive hematopoietic cancers”. The 60% figure travels; the denominator, the sex restriction and the cancers do not.

Established “Partial reprogramming doubled mouse lifespan.” The source reports a 109% increase in median remaining life in mice treated at 124 weeks of age: 8.86 weeks remaining in controls against 18.5 treated. Total median lifespan moves from about 133 weeks to about 142.5 — roughly 7%. The 109% is correctly stated in the paper; the error is entirely downstream, and it is a factor of about fifteen. See Cellular Rejuvenation.

Established “Rapamycin extends lifespan by 9 to 14%, full stop.” It was +14% in females and +9% in males, started at 600 days. Under the transient injection protocol the benefit was male-only. In the human trial the significant findings were in women. Frontier The sex terms are not a footnote; they are the most reproducible structure in the data and they do not currently reconcile.

Established “The TAME trial is under way.” It has never started. Cost $30–50 million; NIH contributed roughly $9 million for biomarker work only; FDA endorsed the concept in 2015; the sponsoring foundation is still soliciting launch funding. This error is held by enthusiasts and by science journalism in equal measure.

Established “Metformin is proven to extend human lifespan.” The supporting evidence is observational and the trial designed to test it has not run. Established Its own designer describes TAME as packaging results already shown, so that a regulator will approve a drug for ageing — a statement about regulatory strategy, not about demonstrated efficacy.

Established “Young blood rejuvenates old animals.” The best-designed experiment in the area replaced roughly half the plasma with saline and albumin, containing nothing young at all, and produced effects that met or exceeded heterochronic blood sharing. Frontier The active principle appears to be removal of age-elevated factors, not addition of youthful ones — which means the young-plasma industry was built on the wrong half of its own mechanism.

Established “Caloric restriction extends lifespan in primates.” Two long-running rhesus studies reached opposite conclusions, and the joint analysis attributes the difference to control feeding (the NIA controls were not free-fed), age at onset, and diet composition — 45% against 7% sucrose as a fraction of carbohydrate. The defensible statement is that caloric restriction improves health markers in primates and that its survival effect depends on the comparator.

Established “Senolytics improved lung function in fibrosis patients.” Six-minute walk distance improved by a mean 21.5 metres and sit-to-stand improved; grip strength and pulmonary function did not change, in an open-label, uncontrolled study of 14 people whose own investigators urged caution about whether the finding was real. Frontier “The senolytics field has a clean human record” fails on two further counts: the most advanced clinical programme was discontinued after phase 2, and a 19-person cohort showed increased epigenetic age acceleration and decreased telomere length.

Frontier “Taurine deficiency drives ageing.” A 2023 Science paper made the case with an accompanying commentary; a 2025 Aging Cell paper is titled “Experimental evidence against taurine deficiency as a driver of aging in humans.” The claim is contested and should be presented that way.

Handwave “There are supplements on the market that extend human lifespan.” There are none. No intervention of any kind — drug, supplement, diet or protocol — has been demonstrated to slow human ageing against a validated endpoint, and that sentence remains true of every compound named in this brief. Frontier The most defensible thing a person can currently do about their own hazard function is exercise, which no candidate in this field has matched in a human trial and which nobody can sell.